Elutia (ELUT) Q4 2024 earnings summary

Executive summary

• EluPro, an FDA-cleared drug-eluting bioenvelope, achieved a strong pilot launch with rapid adoption, representing over 30% of BioEnvelope/device protection sales in Q4 2024 and receiving positive physician feedback.

• Strategic partnership with Boston Scientific will leverage their 900 reps for nationwide EluPro distribution, expected to accelerate adoption and drive significant new account additions.

• SimpliDerm, used in breast reconstruction, grew 12% for the year despite a challenging Q4 due to distributor transition and bankruptcy.

• The company raised $15 million in a direct offering post-Q4, strengthening liquidity and supporting growth initiatives.

• Elutia is focused on expanding EluPro adoption, increasing VAC and GPO approvals, and scaling production capacity, with ongoing business development and partnership discussions.

Financial highlights

• Q4 2024 net sales were $5.5M, down 7% year-over-year; full-year net sales were $24.4M, down 1.5%.

• Device protection/BioEnvelope Q4 sales rose 18% to $2.7M; full-year sales were $9.9M, up 5%.

• SimpliDerm Q4 sales were $2.3M (down 23% year-over-year); full-year sales reached $11.6M, up 12%.

• Cardiovascular product sales were $500,000 in Q4, down 20% year-over-year; full-year sales fell 42%.

• GAAP gross margin improved to 43% in Q4 (from 36% prior year); adjusted gross margin was 58% (vs. 51%).

• Operating expenses were $10.8M in Q4; loss from operations was $8.4M; adjusted EBITDA loss improved to $3.8M from $4.5M year-over-year.

• Net loss from continuing operations was $54.1M for 2024; Q4 net loss was $9.1M.

• Ended Q4 with $13.2M in cash; raised $15M in a direct offering in February 2025.

Outlook and guidance

• Focus for 2025 is on expanding EluPro adoption, increasing VAC and GPO approvals, scaling production, and collecting registry data.

• Boston Scientific partnership expected to drive new account additions and sales growth.

• SimpliDerm expected to recover from Q4 disruption and remain a growth driver.

• No formal financial guidance provided.